Assessing the Clinical and Laboratory Parameters
Was there a prior parathyroidectomy? Low or undetectable PTH levels are an expected finding. Current calcium and phosphate levels are appropriately managed.
Are parathyroids intact (or partially resected/reimplanted during prior parathyroid surgery)? PTH secretion is suppressed, usually secondary to use of calcium based binders and/or use of vitamin D analogues; Parathyroid gland remains sensitive to ambient ionized calcium, i.e. is not autonomous
Approximately 3% of all patients are in this category.
Dialysis Prescription
Lowering the dialysis calcium concentration ( e.g. from 1.25 to 1.0 mmol/L) in this patient may have the effect of providing a stimulus to PTH formation and release.
Phosphate and Calcium Management
Dietary phosphate control, and adherence to prescribed dose of binder is successful.
Phosphate Binders
Therapeutic avenues include;
PTH Management
Vitamin D Sterols
Active 1-hydroxylated vitamin D sterols (calcitriol, 1-alpha) cause direct suppression of PTH. Therapeutic avenues are based on lowering the effective dose;
Calcimimetics
Over suppression of parathyroid glands with a calcimimetic is possible; hypocalcemia with normal Pi control is consistent with this diagnosis
Guideline suggestions include;
CSN
7. Vitamin D sterols can be used in the treatment of secondary hyperparathyroidism, but should be discontinued when PTH levels decrease below target levels, or if calcium or phosphate levels increase above target levels.
(Grade C)
KDIGO
4.2.4.f) We suggest that, if the intact PTH levels fall below two times the upper limit of normal for the assay, calcitriol, vitamin D analogs, and/or calcimimetics be reduced or stopped (2C).
Return to bone and mineral resource home